Acorda celebrates an FDA OK — so does that make them a takeover target?
Late Friday, with the government shutdown looming, the biotech reported that the FDA has approved their inhaled levodopa therapy Inbrija for Parkinson’s patients, putting the company on a short path to a crucially needed market launch.
Acorda $ACOR had been looking at a PDUFA date in early January. But with the FDA racking up a record number of approvals this year — and its third on Friday — the company was given a little bit of an added edge for its 2019 rollout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.